Welcome to our dedicated page for Insight Molecular Diagnostics news (Ticker: IMDX), a resource for investors and traders seeking the latest updates and insights on Insight Molecular Diagnostics stock.
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX), or iMDx, generates news primarily around its work in transplant-focused molecular diagnostics. The company’s updates center on its dd-cfDNA-based GraftAssure assay family, regulatory and reimbursement milestones, clinical data, and collaborations with transplant centers and research partners.
News releases frequently describe progress toward clinical and regulatory goals for the GraftAssureDx in vitro diagnostic kit, including clinical trial activity, software validation, and planned submissions to the U.S. Food and Drug Administration and other regulatory authorities. iMDx also reports on coverage decisions and reimbursement developments for its GraftAssureCore laboratory-developed test, which is performed at the company’s CLIA-certified lab in Nashville.
Investors and clinicians following IMDX news can expect coverage of scientific publications and case studies that use the GraftAssure technology to monitor kidney transplant patients, including complex scenarios involving novel therapies. The company highlights registry initiatives designed to generate real-world dd-cfDNA data, as well as conference presentations where iMDx and its collaborators discuss in-house dd-cfDNA testing and transplant rejection monitoring.
Additional IMDX news items include corporate developments such as executive appointments, participation in healthcare and investor conferences, and strategic updates related to the company’s transplant rejection testing strategy. For readers interested in the diagnostics and research sector, the IMDX news feed offers ongoing insight into how dd-cfDNA assays are being developed, validated, and positioned for use in kidney transplant management.
iMDx (Nasdaq: IMDX) has announced a virtual Key Opinion Leader (KOL) event scheduled for August 15, 2025, at 4:00 PM ET. The event will feature Dr. Anthony Langone, Associate Professor at Vanderbilt University and national principal investigator for iMDx's kidney transplant monitoring trial.
The presentation will focus on the company's GraftAssure™ testing platform, which uses digital PCR technology for donor-derived cell-free DNA (dd-cfDNA) transplant monitoring. Management will discuss their strategy for in-house testing capabilities and the development of a diagnostic test kit for clinical use. A Q&A session will follow the presentations, with advance questions accepted via email.
iMDx (NASDAQ:IMDX) announced positive results from a head-to-head study comparing its GraftAssureIQ digital PCR-based test kit with NGS-based technology for kidney transplant rejection testing. The study, conducted at University Hospital Heidelberg, evaluated 96 kidney transplant recipients and demonstrated equivalent measurements between the two platforms in detecting donor-derived cell-free DNA (dd-cfDNA).
The company's digital PCR technology showed improved analytical sensitivity in detecting dd-cfDNA in low quantities. This data supports iMDx's preparation for commercial launch following expected regulatory approval in 2026, targeting the estimated $1 billion transplant rejection testing market. Extended study data will be presented at the upcoming European Society of Organ Transplantation Congress in London.